Form 8-K

8-K — Traws Pharma, Inc.

Accession: 0001104659-26-043781

Filed: 2026-04-15

Period: 2026-04-15

CIK: 0001130598

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — tm2611843d2_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2611843d2_ex99-1.htm)

GRAPHIC (tm2611843d2_ex99-1img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2611843d2_8k.htm · Sequence: 1

false

0001130598

2026-04-15

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):

April 15, 2026

Traws

Pharma, Inc.

(Exact name of Registrant as specified in its

charter)

Delaware

001-36020

22-3627252

(State or Other Jurisdiction

of Incorporation or Organization)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

12 Penns Trail

Newtown, PA 18940

(267)

759-3680

(Address,

Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive

Offices)

Not Applicable

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common

stock, par value $.01 per share

TRAW

The

Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2

of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition.

The information provided below in “Item

7.01 - Regulation FD Disclosure” of this Current Report on Form 8-K (this “Current Report”) regarding the Earnings Release

is incorporated by reference into this Item 2.02.

Item 7.01 Regulation FD Disclosure.

On April 15, 2026, Traws Pharma, Inc. (the

“Company”) issued a press release (the “Earnings Release”) announcing its financial results for the fiscal year

ended December 31, 2025, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”)

and incorporated herein by reference.

The information set forth under

Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed”

for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to

the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated

by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference

language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed

an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.

Forward-Looking Statements

This Current Report, including

Exhibit 99.1, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms

“anticipates,” “expects,” “estimates,” “believes,” “will” and similar expressions,

as they relate to the Company or its management, are intended to identify such forward-looking statements.

Forward-looking statements in this Current Report,

including Exhibit 99.1, or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission,

reports to the stockholders of the Company and other publicly available statements issued or released by the Company involve known and

unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating)

or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking

statements. Such future results are based upon management’s best estimates based upon current conditions and the most recent results

of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Securities

and Exchange Commission, each of which could adversely affect the Company’s business and the accuracy of the forward-looking statements

contained herein.

Item 9.01 Financial

Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press

Release, dated April 15, 2026

104

Cover

Page Interactive Data File (embedded within the inline XBRL Document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange

Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 15, 2026

TRAWS PHARMA, INC.

By:

/s/ Iain Dukes

Iain Dukes

Chief Executive Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2611843d2_ex99-1.htm · Sequence: 2

Exhibit 99.1

Traws

Pharma Reports Full Year 2025 Results

and Provides Business Highlights

Tivoxavir

marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral

activity,

Ratutrelvir

topline Phase 2a data show a differentiated profile versus PAXLOVID® in COVID patients, with good overall safety; final study analysis

underway

Private financing of up to $60M (with $10M

of such amount upfront) offering of common stock and milestone-based and three-year warrants completed on April 15, 2026 supporting

operations into Q1 2027

Investor

Update call today, April 15, 2026 at 4:30 PM ET

NEWTOWN, PA, April

15, 2026 (GLOBE NEWSWIRE) – Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the

Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from

respiratory viral diseases, today reported financial results for the year ended December 31, 2025 and provided recent business highlights

including updates for the Company’s lead investigational program: tivoxavir marboxil (TXM) in development for influenza prophylaxis

and treatment, and completion of a private investment in public equity (PIPE) financing providing up to $60 million in gross proceeds,

including $10 million in gross proceeds at closing. The financing, plus current cash and cash equivalents, is expected to provide sufficient

resources to support Company operations into Q1 2027, including completion of the planned Phase 2a single-dose human Challenge Trial for

TXM as a once-monthly oral prophylactic agent for influenza prevention (“Challenge Trial”).

“Traws has

made substantial progress over the last year, towards our goal of advancing our potential best-in-class influenza program as a prophylactic

agent. The bridging study for the new compressed tablet formulation is currently underway in Australia. In parallel, the Company expects

the planned Challenge Trial to proceed as scheduled in the second quarter of 2026, subject to formal approval from the United Kingdom

Medicines and Healthcare products Regulatory Agency (“MHRA”). Additionally, we are actively engaging with the U.S.

Food and Drug Administration to resolve the clinical hold and support advancement of the TXM program in the U.S.,” commented Iain

Dukes, MA, DPhil, Chief Executive Officer of Traws Pharma. “The capital from the recent private financing, supported by

a group of new and existing investors, positions Traws to complete the Challenge Trial, while preserving access to substantial additional

capital as key milestones are achieved.”

Conference

Call and Webcast Information

· Date:

Wednesday, April 15, 2026, at 4:30 PM ET

· Participant

Dial-in (U.S.): 1-877-407-0789

· Participant

Dial-in (International): 1-201-689-8562

· Webcast

Access: Click Here

replay of the webcast will be available on the Investors section of the Traws website at https://www.trawspharma.com/corporate-events-presentations.

Recent

Highlights and Anticipated Milestones:

$60

Million Private Financing

On April 15, 2026, TRAW announced an up to $60

million PIPE financing including initial funding of $10 million in gross proceeds at closing, with up to approximately $50 million of

additional potential gross proceeds from milestone-based and three-year warrants. The financing consists of the sale of 5,982,919 shares

of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.6730 per share, with the warrant exercise price equal

to the deal price, as follows:

· Series A

milestone-based warrant with an aggregate exercise price of $10.0 million that becomes exercisable

upon receipt of approval from MHRA to conduct the challenge trial.

· Series B

milestone-based warrant with an aggregate exercise price of $10.0 million that becomes exercisable

following both shareholder approval and the announcement of data from the challenge trial.

· Series C

common warrants with a three-year term to purchase shares of our common stock and providing

potential additional gross proceeds of $30.0 million if fully exercised following

shareholder approval.

The upfront gross proceeds and milestone-based

warrants, along with the current cash and cash equivalents, are estimated to provide sufficient resources to fund company operations into

Q1 2027 including completion of a human challenge trial for TXM as a once-monthly prophylactic agent for influenza prevention. The terms

of the financing are described in more detail in the Company’s current report on Form 8-K filed in connection with the financing

on April 15, 2026.

Investigational

Programs:

Tivoxavir

Marboxil (TXM, influenza):

Intended

Indication and Market Potential: Potential as a best-in-class once-monthly prophylactic or treatment for seasonal flu and pandemic/bird

flu, estimated to be a multi-billion dollar opportunity, including potential for stockpiling and pandemic preparedness initiatives.1,2

Recent

Developments: New Formulation Supports Planned Prophylactic Treatment Study

Recently

completed preclinical studies show that the new TXM compressed tablet formulation provides longer exposure and extended coverage against

influenza. This new formulation, coupled with broad preclinical activity previously demonstrated against a wide range of influenza strains,

including all influenza A and B strains, supports TXM’s potential use as a once-monthly prophylactic treatment for seasonal flu.

Traws

also continues to advance the program for TXM as a single-dose oral therapy for seasonal flu or H5N1 bird flu, including efforts to secure

formal consideration by the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in the U.S. stockpile, with

a focus on resolving the clinical hold by the U.S. FDA.

Steps:

· Completion

of Phase 1 Bridging Study – The ongoing Phase 1 bridging study, being conducted

under an open IND in Australia, is intended to recapitulate the preclinical data and confirm

that the new compressed tablet formulation can provide 28-days of coverage, enabling TXM’s

use as a once-monthly prophylactic treatment.

· MHRA

Approval and Initiation of Challenge trial – TRAW will conduct a single-dose influenza

virus challenge trial of TXM at hVIVO, in the UK, following completion of the Phase 1 Bridging

study and receipt of MHRA approval. hVIVO is global leader in the conduct of human challenge

studies for infectious diseases and respiratory viruses.

· Efforts

Ongoing to Resolve the Clinical Hold – FDA informed the Company that its U.S. IND

for TXM has been placed on clinical hold due to concerns with the toxicology data package.

The Company plans to engage with the FDA to address the clinical hold and is working to develop

and submit a comprehensive response, with the goal of resolving the hold and advancing the

program in the U.S. during 2026.

Ratutrelvir

(COVID):

Intended Indication and Market Potential: Potential

as a once-daily, ritonavir-independent oral Main protease (Mpro) inhibitor for the treatment of acute COVID infection in a broad range

of patients, including those who are PAXLOVID®-ineligible, with potential to reduce the risk of COVID rebound and Long

COVID, estimated to be a multi-billion dollar opportunity.3

Recent

Developments: Positive Phase 2a Results

Traws

is completing final analysis of the 90-patient Phase 2a study. Topline data demonstrated safety and proof-of-concept efficacy for ratutrelvir

in PAXLOVID®-eligible and PAXLOVID®-ineligible patients. Patients ineligible to receive PAXLOVID® are frequently at

elevated risk for severe disease and require suitable, safe and effective treatment options. Ratutrelvir has the potential to address

this gap in care and may be a valuable therapeutic option.

The

Phase 2a study was designed as an active-controlled comparator trial versus PAXLOVID® (nirmatrelvir/ritonavir), evaluating

patient-reported symptom outcomes, safety, and real-world usability. A separate treatment arm was comprised of patients ineligible for

ritonavir-boosted regimens due to contraindications or clinically significant drug–drug interactions. Topline data showed:

· Efficacy:

Ratutrelvir demonstrated equivalent time to sustained treatment resolution with no viral

rebounds in PAXLOVID® eligible subjects. The study also showed that treatment with ratutrelvir

produced faster symptom resolution in PAXLOVID®-ineligible patients (HR, 1.31; 95% CI,

0.78-2.20, p=0.018).

· Safety:

Ratutrelvir demonstrated favorable overall safety, with fewer treatment related adverse events

compared to PAXLOVID®.

Steps:

· Phase

2 Data Support Further Development of Ratutrelvir – Traws plans to use the resulting

data from the final analysis of the Phase 2a study to inform next steps for its clinical

and regulatory strategy.

Corporate

Updates:

· John

Leaman, MD, named Independent Board Director on October 6, 2025, bringing significant

expertise in finance, M&A and corporate strategy.

· Appointment

of Iain Dukes, MA, D Phil, as CEO, and Charles Parker, as CFO, confirmed by the Board on

October 6, 2025.

Financial

Results:

Cash and cash

equivalents: As of December 31, 2025, the Company had cash and cash equivalents of approximately $3.8 million, compared to

approximately $21.3 million as of December 31, 2024, excluding gross proceeds of up to approximately $60 million for a PIPE financing

and milestone-based and three-year warrants which the Company completed on April 15, 2026, with funding thereunder expected April 16,

2026. Based on current plans, the Company believes that its current cash balance, including net proceeds from the offering and milestone-based

warrants, is sufficient to support planned expenses, including completion of the Challenge Study, into Q1 2027.

Revenue

for the year ended December 31, 2025, was $2.8 million, compared to $0.2 million for the comparable period in 2024. The increase

in 2025 revenue was due to the recognition of deferred revenue as a result of the termination of the Symbio license agreement.

Acquired

in-process research and development expense for the year ended December 31, 2025 was zero compared to $117.5 million for the

comparable period in 2024, recognized related to virology programs acquired in connection with the acquisition of Trawsfynydd through

a merger.

Research

and development (R&D) expense for the year ended December 31, 2025, totaled $12.1 million, compared to $12.8 million for

the comparable period in 2024. This decrease of $0.7 million primarily relates to a decrease in expenses related to the oncology programs,

partially offset by an increase in expenses related to the virology programs.

General and administrative

(G&A) expense for the year ended December 31, 2025, totaled $8.5 million, compared to $12.3 million for the comparable

period in 2024. This decrease of $3.8 million was primarily attributable to a decrease in professional and consulting fees.

Net

Income (loss): The net income for the year ended December 31, 2025 was $9.2 million, or net income of $0.83 per basic common

and $0.82 per diluted common share. This compares to net loss of $166.5 million, or a net loss of $35.21 per basic and diluted common

share, for the year ended December 31, 2024.

Outstanding: Traws had 10,157,257 shares of common stock outstanding as of April 14, 2026.

About

Tivoxavir Marboxil

Tivoxavir

marboxil (TXM) is an investigational oral, small molecule CAP-dependent endonuclease inhibitor designed to be administered as a single-dose

agent for prophylactic use or treatment of seasonal influenza and pandemic/bird flu. It has shown potent in vitro activity against

a range of influenza strains in preclinical studies, including a human isolate of the highly pathogenic avian flu H5N1 (bird flu). Consistent,

positive preclinical data from three animal species indicate that a single dose of TXM demonstrated a therapeutic effect against H5N1

bird flu. Seasonal influenza represents an estimated multi-billion dollar antiviral market opportunity, largely driven by global health

organizations, practice guidelines and government tenders and inclusion in drug stock piling initiatives1,2, with upside potential

from potential pandemic flu outbreaks including H5N1 bird flu.

About

Ratutrelvir

is an investigational oral, small molecule Mpro (3CL protease) inhibitor designed to be a broadly acting treatment for SARS-CoV-2/COVID-19

that is used without ritonavir. It has demonstrated in vitro activity against a range of virus strains. Preclinical and Phase

1 studies show that ratutrelvir does not require co-administration with a metabolic inhibitor, such as ritonavir, which could avoid ritonavir-associated

drug-drug interactions4, and potentially enable wider patient use. Phase 1 data also show that ratutrelvir’s pharmacokinetic

(PK) profile demonstrated maintenance of target blood plasma levels approximately 13 times above the EC50 using the target

Phase 2 dosing regimen of 600 mg/day for ten days, which may also reduce the likelihood of clinical rebound and, consequently, reduce

the risk for Long COVID5. Industry data indicate that COVID treatment represents a potential multi-billion dollar market opportunity3.

Source

information

1. Per

link

2. Traws

data on file

3. Pfizer

Inc. annual report on Form 10-K for the fiscal year ended December 31, 2025, filed

with the U.S. Securities and Exchange Commission on February 3, 2026

4. https://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2646

5. Carly

Herbert et al. (2025) Clinical Infectious Diseases. https://pubmed.ncbi.nlm.nih.gov/39692474/

Third-party

products mentioned herein are the trademarks of their respective owners.

About

Traws Pharma, Inc.

Traws

Pharma is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health

in respiratory viral diseases. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to meet real

world challenges in the treatment of viral diseases. We are advancing novel investigational oral small molecule antiviral agents that

have potent activity against difficult to treat or resistant virus strains that threaten human health: seasonal influenza and H5N1 bird

flu, and COVID-19/Long COVID. Tivoxavir marboxil is in development as a once-monthly oral prophylactic agent for influenza prevention,

with additional potential as a single-dose therapy for seasonal flu or H5N1 bird flu, targeting the influenza cap-dependent endonuclease

(CEN). Ratutrelvir is in development as a ritonavir-independent COVID treatment, targeting the Main protease (Mpro or 3CL protease).

Traws

is actively seeking development and commercialization partners for its legacy clinical oncology programs, rigosertib and narazaciclib.

More details can be found on Traws’ website at https://www.ir.trawspharma.com/partnering.

For

more information, please visit www.trawspharma.com and follow us on LinkedIn.

Forward-Looking

Statements

Some

of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,

as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of

1995, and involve risks and uncertainties including statements regarding the Company, its business and product candidates, including

the potential opportunity, market size, benefits, effectiveness, safety, and the clinical and regulatory plans for tivoxavir marboxil

and ratutrelvir, as well as plans for its legacy programs. The Company has attempted to identify forward-looking statements by terminology

including “believes”, “estimates”, “anticipates”, “expects”, “plans”, “intends”,

“may”, “could”, “might”, “will”, “should”, “preliminary”, “encouraging”,

“approximately” or other words that convey uncertainty of future events or outcomes. Although Traws believes that the expectations

reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different

from the results expressed or implied by such forward looking statements. These statements are only predictions and involve known and

unknown risks, uncertainties, and other factors, including the outcome of Traws’ IND filing with the FDA for tivoxavir marboxil,

including the current FDA clinical hold; the success and timing of Traws’ clinical trials; the potential efficacy of ratutrelvir

for the treatment of COVID-19, including the potential to reduce the risk of COVID rebound and Long COVID; the potential for ratutrelvir

to gain market acceptance, if and when regulatory approval is obtained, or to become the new standard of care; Traws’ interactions

with the FDA, BARDA and similar foreign regulators; collaborations; market conditions; regulatory requirements and pathways for approval;

the ongoing need for improved therapy to reduce the frequency of clinical rebound and the concomitant risk for Long COVID; the extent

of the spread and threat of the bird flu; the Company’s cash projections; Traws’ ability to raise additional capital when

needed; and those discussed under the heading “Risk Factors” in Traws’ filings with the U.S. Securities and Exchange

Commission (SEC). Any forward-looking statements contained in this release speak only as of its date. Traws undertakes no obligation

to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to

reflect the occurrence of unanticipated events, except to the extent required by law.

Traws

Pharma Contact:

Charles

Parker

Traws

Pharma, Inc.

cparker@trawspharma.com

www.trawspharma.com

Investor

Contact:

John

Fraunces

LifeSci Advisors, LLC

917-355-2395

jfraunces@lifesciadvisors.com

Traws

Pharma, Inc.

Condensed

Consolidated Balance Sheets

December 31,

2025

2024

Assets

Current assets:

Cash and cash equivalents

$ 3,820,000

$ 21,338,000

Tax incentive and other receivables

3,794,000

1,765,000

Prepaid expenses and other assets

365,000

1,848,000

Total current assets

7,979,000

24,951,000

Property and equipment, net

7,000

10,000

Intangible assets, net

2,527,000

—

Other assets

104,000

1,000

Total assets

$ 10,617,000

$ 24,962,000

Liabilities and stockholders’ deficit

Current liabilities:

Accounts payable

$ 5,653,000

$ 8,186,000

Accrued expenses and other liabilities

5,493,000

3,121,000

Deferred revenue

—

226,000

Total current liabilities

11,146,000

11,533,000

Deferred revenue, non-current

—

2,565,000

Warrant liabilities

100,000

42,494,000

Total liabilities

11,246,000

56,592,000

Commitments and contingencies (Note 6)

Stockholders’ deficit:

Series C Preferred stock, $0.01 par value, 5,000,000 shares authorized, 7,440 shares issued and 6,737 shares outstanding at December 31, 2025 and 7,440 shares issued and 7,398 outstanding at December 31, 2024

—

Common stock, $0.01 par value, 250,000,000 shares authorized, 9,067,774 and 3,650,731 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively

90,000

36,000

Additional paid in capital

639,259,000

617,530,000

Accumulated deficit

(639,984,000 )

(649,154,000 )

Accumulated other comprehensive income (loss)

6,000

(42,000 )

Total stockholders’ deficit

(629,000 )

(31,630,000 )

Total liabilities and stockholders’ deficit

$ 10,617,000

$ 24,962,000

Traws

Pharma, Inc.

Condensed

Consolidated Statements of Operations

Years ended December 31,

2025

2024

Revenue

$ 2,790,000

$ 226,000

Operating expenses:

Acquired in-process research and development

—

117,464,000

Research and development

12,143,000

12,847,000

General and administrative

8,522,000

12,289,000

Total operating expenses

20,665,000

142,600,000

Loss from operations

(17,875,000 )

(142,374,000 )

Change in fair value of warrant liability

26,567,000

—

Series A warrant and pre-funded warrant expense

—

(24,438,000 )

Other income, net

478,000

289,000

Net income (loss)

$ 9,170,000

$ (166,523,000 )

Net income (loss) attributable to common stockholders, basic and diluted

$ 6,865,000

$ (54,674,000 )

Weighted-average shares of common stock outstanding, basic

8,228,169

1,552,685

Net income (loss) per share of common stock, basic

$ 0.83

$ (35.21 )

Weighted-average shares of common stock outstanding, diluted

8,376,380

1,552,685

Net income (loss) per share of common stock, diluted

$ 0.82

$ (35.21 )

Net income (loss) attributable to Series C Preferred stockholders, basic and diluted

$ 2,305,000

$ (111,849,000 )

Weighted-average shares of Series C Preferred outstanding, basic and diluted

6,906

7,941

Net income (loss) per share of Series C Preferred, basic and diluted

$ 333.77

$ (14,085.00 )

GRAPHIC

Filename: tm2611843d2_ex99-1img001.jpg · Sequence: 3

Binary file (10960 bytes)

Download tm2611843d2_ex99-1img001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Apr. 15, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 15, 2026

Entity File Number

001-36020

Entity Registrant Name

Traws

Pharma, Inc.

Entity Central Index Key

0001130598

Entity Tax Identification Number

22-3627252

Entity Incorporation, State or Country Code

Entity Address, Address Line One

12 Penns Trail

Entity Address, City or Town

Newtown

Entity Address, State or Province

Entity Address, Postal Zip Code

18940

City Area Code

267

Local Phone Number

759-3680

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

stock, par value $.01 per share

Trading Symbol

TRAW

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration